摘要
目的探讨米氮平合并小剂量舒必利治疗以胃肠道症状为主诉的抑郁症的疗效及安全性。方法将80例以胃肠道症状为主诉的抑郁症患者随机分为研究组(米氮平合并舒必利)和对照组(米氮平)各40例,疗程8周。用17项汉密尔顿抑郁量表(HAMD-17)判定疗效,用治疗中需处理的不良反应症状量表(TESS)评定不良反应。结果治疗后第1周末研究组HAMD总分及焦虑/躯体化、睡眠障碍因子分均较治疗前降低(P<0.05);治疗后第2、4、8周末两组HAMD总分及各因子分均较各自治疗前降低,且研究组低于对照组(P<0.01)。两组痊愈率比较差异无统计学意义(P>0.05)。两组总不良反应发生率比较差异无统计学意义(P>0.05)。结论米氮平合并小剂量舒必利治疗以胃肠道症状为主诉的抑郁症的疗效优于单用米氮平,且起效较快。
Objective To explore the efficacy and safety of mirtazapine plus small-dose sulpiride in the treatment of depression with complain of gastrointestinal symptoms. Methods 80 depressive patients with complain of gastrointestinal symptoms were randomly divided into study group （ n = 40） treated with mirtazapine plus small-dose sulpiride and control group （n =40） treated with mirtazapine monotherapy for 8 weeks. Hamilton Depression Scale-17 items （HAMD-17） was used to evaluate the efficacy and Treatment Emergent Symptom Scale （TESS） was used to evaluate the adverse reactions. Results At the end of the 1 at week of the treatment, total score of HAMD and factor scores of anxiety/somatization, sleep disturbance in study group decreased significantly when compared with the baseline （ P 〈 0.05 ）. At the end of the 2nd, 4th, 8th week of the treatment, total score and all factor scores of HAMD in both groups decreased significantly compared with the baseline respectively. Total score and all factor scores of HAMD in study group were significantly lower than those in control group at the end of the 2nd 4th 8th week （P 〈 0.01 ）. There was no significant difference in recovery rate and incidence rate of adverse reactions between the two groups （P 〉 0.05 ）. Conclusion Mirtazapine plus small-dose sulpiride has better efficacy and takes effect more rapidly than mirtazapine monotherapy in the treatment of depression with complain of gastrointestinal symptoms.
出处
《精神医学杂志》
2015年第6期443-445,共3页
Journal of Psychiatry
